10th Conference of the European Hidradenitis Suppurativa Foundation e.V. (virtual)
February 10-12, 2021

Organizing Committee
Gregor B.E. Jemec, Roskilde
Veronique del Marmol, Brussels
Errol P. Prens, Rotterdam
Thrasyvoulos Tzellos, Tromsø
Christos C. Zouboulis, Dessau

Overall learning objectives
• To present the most current research on the etiology of HS to new treatments
• To discuss and exchange opinions on innovations, discoveries and HS treatment regimens in an international setting
• To address HS unmet needs and future collaborative projects and developments

Wednesday, February 10, 2021
08.00-18.00 (CET)
• Sponsor Exhibition (digital booths) – Meetings with Sponsor Representatives
• Sponsor-supported scientific and commercial sessions
• Advisory Boards
• Presentation of 10th EHSF Abstract Book
• Poster Viewing
• Patient Association Representatives Chat Room

360o perspectives on challenging HS cases: Sophia, High Inflammatory. What happened next?
Speakers: Dr Savage, Dr Tzellos, Dr Rivitti Machado, Dr Becherel, Dr Van Der Zee, Dr Hayashi, Dr Alharithy

360o perspectives on challenging HS cases: Adam, Combination Therapy. What happened next?
Speakers: Dr Martorell, Dr Suppa, Dr Bechara, Dr Arenbergerova, Dr Smith, Dr Matusiak, Dr Bettoli

Thursday, February 11, 2021
08.00-09.00 (CET) EHSF e.V. General Assembly
09.00-10.00 (CET) HS Nursing School
10.00-10.10 (CET) Welcome Address
10.10-10.30 (CET) Opening lecture: 15 years hidradenitis suppurativa: Then and today - Errol P. Prens (Rotterdam)
10.30-13.30 (CET) Scientific Session 1 – Epidemiology and Diagnostic Tools (Clinical Phenotypes, Outcome Measures)
Main learning objectives of this session are
- to communicate new data on HS epidemiology, clinical phenotypes and comorbidities
- to present the development on more robust outcome measures
- to present new physician- and patient-supporting assessment technologies
Epidemiology - Ingram (Cardiff) - Jfri O’Brien (Montreal)
Phenotypes – van der Zee (Rotterdam) – Naldi (Bergamo)
Comorbidities – Frew (Sydney) - Glasenhardt (Szeged)
Outcome measures – Jemec (Roskilde) - Tzellos (Tromsø)
HS Apps (Classification, Pain) – Hórvath (Groningen) – Zouboulis (Dessau)
Selected abstracts
13.30-15.00 (CET) Poster Session
15.00-18.00 (CET)  Scientific Session 2 – Basic and Translational Experimental Research (Genetics, Immunology, Biomarkers Co-morbidities, Registries)

**Main learning objectives of this session are**
- to learn what is new on HS genetics and biomarker research  
- to evaluate specific fields of HS, such as syndromic and pediatric varieties  
- to communicate the current status and procedures in the development of HS registries and how they can support HS research

Genetics/Biomarkers – Szegedi (Debrecen) - Hüe (Créteil)  
Immunology - Byrd (Washington DC)  
Syndromic HS – Marzano (Milan) – Nikolakis (Dessau)  
Pediatric HS – Saunte (Roskilde) – Benhadou (Brussels)  
Registries – del Marmol (Brussels)

Selected Abstracts

18.00-20.00 (CET)  Advisory Boards

• Sponsor Exhibition (digital booths) – Meetings with Sponsor Representatives  
• Poster Viewing

**Friday, February 12, 2021**

08.00-10.00 (CET)  Poster Session

10.00-13.00 (CET)  Scientific Session 3 – HS around the World (Selected International Contributions)

**Main learning objectives of this session are**
- to communicate specific issues on HS epidemiology, clinical picture and treatment in different populations and geographic areas of the world  
- to exchange the knowledge development and built up and corroborate international cooperations

South Asian perspective - Chandran (Singapore)  
Chinese perspective – Wang (Peking)  
USA perspective – Kirby (Hershey)  
Canadian perspective - Kirchhof (Ottawa)

Selected abstracts

13.00-15.00 (CET)  Scientific Symposium on HS treatment target molecules and Anti-COVID-19 Measurements

15.00-18.00 (CET)  Scientific Session 4 – Treatment Innovations (Clinical Trials, Systemic Treatment, Surgical Treatment, Imaging)

**Main learning objectives of this session are**
- to summarize the new evidence on biologic, systemic and surgical treatments, their implications in daily clinical practice and how they can shape current treatment strategies and promote better combination of medical and surgical approaches.  
- to provide an overview of the current pipeline (phase 2 and 3 studies)  
- to discuss how imaging could facilitate rational treatment decision making 

Clinical trials - Gulliver (St. John’s) - Giamarellos-Bourboulis (Athens)  
Topical treatment/LAight – Matusiak (Wroclaw)  
Antibiotic treatment –Join-Lambert (Caen) - Van Straalen (Rotterdam)  
Surgery – Guillem (Lyon) – Podda (Darmstadt)  
Imaging technologies - Martorell (Valencia) – Wild (Dessau)  

Selected abstracts

18.00-19.00 (CET)  Selected Poster Session – Poster Prizes

19.00-19.15 (CET)  Conference Closing/Announcements

• Sponsor Exhibition (digital booths) – Meetings with Sponsor Representatives  
• Poster Viewing